Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)
ANNALS OF ONCOLOGY, vol.33, no.7, 2022 (SCI-Expanded)
- Publication Type: Article / Abstract
- Volume: 33 Issue: 7
- Publication Date: 2022
- Doi Number: 10.1016/j.annonc.2022.07.1097
- Journal Name: ANNALS OF ONCOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
- Open Archive Collection: AVESIS Open Access Collection
- Istanbul University Affiliated: No